New online program aims to boost genetic cancer testing in african american families
NCT ID NCT07542405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a web-based program called Kindred that helps African American families understand their genetic cancer risk and talk about testing. About 150 people will use the tool to see if it improves knowledge and testing rates. The goal is to make genetic information more accessible and reduce health disparities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing * PROBANDS: \>= 18-years-old * PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results * PROBANDS: Able to speak and read English * PROBANDS: Access to the internet * PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities) * RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing * RELATIVES: \>= 18 years old * RELATIVES: Able to speak and read English * RELATIVES: Access to the internet Exclusion Criteria: * PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative * PROBANDS: Under 18-years-old * PROBANDS: Did not receive cancer genetic testing * PROBANDS: Does not speak or read English * PROBANDS: Does not have internet access * PROBANDS: Does not identify as African American or Black * RELATIVES: Not a biological relative of proband * RELATIVES: Under 18-years-old * RELATIVES: Does not speak or read English * RELATIVES: Does not have internet access
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1-related hereditary breast and ovarian cancer syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A watchful eye: could alternating scans outsmart pancreatic cancer?
- Can a walking routine alter cancer biomarkers? new trial investigates
- Digital assistant aims to close gaps in hereditary cancer care
- Lynch syndrome patients share colonoscopy struggles in new survey
- Personalized vaccine aims to stop lynch syndrome cancers before they start
- Swiss study aims to find hidden cancer genes in families